Bruker 8-K

Leadership change

Board adds immunologist Eicke Latz as life-science work expands; declares $0.05/share quarterly dividend.

Filed 2026-11-16 07:00 ET

Summary

Board expansion and quarterly dividend declaration. Bruker added one seat to expand its Board to 12 and appointed Eicke Latz, an immunology scientist and co-founder of five biotechnology companies, effective 1/1/2027; he will serve through the 2029 Annual Meeting and receive compensation consistent with other non-employee directors. The appointment brings scientific and biopharma experience as Bruker expands its work in life-science tools, disease biology research, molecular diagnostics and drug discovery.

The Board declared a $0.05-per-share dividend on 11/12/2026, payable 1/7/2027 to shareholders of record on 12/21/2026.

Was this summary useful?

The summary is written by an AI model reading the filing.

Model 005 · prompt v192 · 2026-11-16 15:36:46Z

Feedback